KORU Medical Systems (NASDAQ:KRMD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of KORU Medical Systems (NASDAQ:KRMD) from a buy rating to a strong-buy rating in a report released on Saturday.

A number of other equities analysts have also recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of KORU Medical Systems in a report on Thursday, January 22nd. Craig Hallum reiterated a “buy” rating and set a $7.00 price target on shares of KORU Medical Systems in a research note on Tuesday, January 13th. Lake Street Capital increased their price target on shares of KORU Medical Systems from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. B. Riley Financial raised their price objective on shares of KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $6.00 price objective on shares of KORU Medical Systems in a report on Friday, March 13th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, KORU Medical Systems currently has an average rating of “Moderate Buy” and a consensus price target of $6.50.

KORU Medical Systems Stock Performance

KORU Medical Systems stock opened at $4.26 on Friday. The company has a market capitalization of $198.56 million, a PE ratio of -71.00 and a beta of 0.55. KORU Medical Systems has a fifty-two week low of $2.18 and a fifty-two week high of $6.61. The firm has a 50 day moving average price of $4.47 and a 200 day moving average price of $4.85.

KORU Medical Systems (NASDAQ:KRMD) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01. KORU Medical Systems had a negative return on equity of 15.90% and a negative net margin of 6.41%.The company had revenue of $10.90 million for the quarter, compared to analysts’ expectations of $10.90 million. As a group, equities research analysts forecast that KORU Medical Systems will post -0.03 earnings per share for the current year.

Institutional Investors Weigh In On KORU Medical Systems

Large investors have recently bought and sold shares of the stock. Invesco Ltd. boosted its stake in shares of KORU Medical Systems by 24.8% in the 4th quarter. Invesco Ltd. now owns 27,873 shares of the company’s stock valued at $162,000 after buying an additional 5,546 shares during the period. Occudo Quantitative Strategies LP purchased a new stake in shares of KORU Medical Systems during the fourth quarter worth approximately $127,000. Price T Rowe Associates Inc. MD increased its stake in shares of KORU Medical Systems by 26.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,036 shares of the company’s stock worth $158,000 after buying an additional 5,649 shares during the period. Russell Investments Group Ltd. raised its holdings in KORU Medical Systems by 28.3% in the fourth quarter. Russell Investments Group Ltd. now owns 195,773 shares of the company’s stock valued at $1,137,000 after acquiring an additional 43,215 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in KORU Medical Systems by 8,719.9% in the fourth quarter. Royal Bank of Canada now owns 133,004 shares of the company’s stock valued at $773,000 after acquiring an additional 131,496 shares in the last quarter. Hedge funds and other institutional investors own 58.60% of the company’s stock.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.